NCT04362345

Brief Summary

The aim of the research is to improve patient management by rapidly identifying, based on the terrain and clinical and biological characteristics, those patients likely to present a severe form of ARDS at risk of leading to intensive care

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 9, 2020

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

April 20, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 24, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 9, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 9, 2021

Completed
Last Updated

December 28, 2020

Status Verified

April 1, 2020

Enrollment Period

9 months

First QC Date

April 20, 2020

Last Update Submit

December 24, 2020

Conditions

Keywords

Covid_19SARS-CoV-2ARDSrisk factorsinfection

Outcome Measures

Primary Outcomes (1)

  • Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection

    Files analysed retrospectively from March 1st, 2020 to April 15, 2020 will be examined]

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult Patients with Covid-19

You may qualify if:

  • Major patient (≥18 years of age)
  • Admitted in March 2020 for confirmed Covid-19 lung disease (nasopharyngeal smear or sputum with SARS-CoV-2 positive PCR).

You may not qualify if:

  • Patient who has expressed opposition to participation in the study.
  • Mild forms of infection that do not require hospitalization,
  • Subject under safeguard of justice
  • Subject under guardianship or trusteeship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service des Maladies Infectieuses et Tropicales

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

COVID-19Infections

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2020

First Posted

April 24, 2020

Study Start

April 9, 2020

Primary Completion

January 9, 2021

Study Completion

January 9, 2021

Last Updated

December 28, 2020

Record last verified: 2020-04

Locations